CY1124301T1 - Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων - Google Patents
Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμωνInfo
- Publication number
- CY1124301T1 CY1124301T1 CY20211100601T CY211100601T CY1124301T1 CY 1124301 T1 CY1124301 T1 CY 1124301T1 CY 20211100601 T CY20211100601 T CY 20211100601T CY 211100601 T CY211100601 T CY 211100601T CY 1124301 T1 CY1124301 T1 CY 1124301T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tendon
- indazole compounds
- ligament injuries
- present
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Η παρούσα εφεύρεση παρέχει μια ένωση του τύπου (Ι) σε ελεύθερη μορφή ή σε φαρμακευτικώς αποδεκτή μορφή άλατος (Ι), μια μέθοδο παρασκευής των ενώσεων της εφεύρεσης και τις θεραπευτικές χρήσεις αυτής. Η παρούσα εφεύρεση παρέχει περαιτέρω έναν συνδυασμό φαρμακολογικώς δραστικών παραγόντων και μιας φαρμακευτικής σύνθεσης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398869P | 2016-09-23 | 2016-09-23 | |
| PCT/IB2017/055735 WO2018055550A1 (en) | 2016-09-23 | 2017-09-21 | Indazole compounds for use in tendon and/or ligament injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124301T1 true CY1124301T1 (el) | 2022-07-22 |
Family
ID=60084023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100601T CY1124301T1 (el) | 2016-09-23 | 2021-07-05 | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US10112907B2 (el) |
| EP (1) | EP3515894B1 (el) |
| JP (1) | JP7007374B2 (el) |
| KR (1) | KR102490953B1 (el) |
| CN (1) | CN109715608B (el) |
| AR (1) | AR109688A1 (el) |
| AU (1) | AU2017332867B2 (el) |
| BR (1) | BR112019005578A2 (el) |
| CA (1) | CA3033249A1 (el) |
| CL (1) | CL2019000727A1 (el) |
| CO (1) | CO2019002616A2 (el) |
| CR (1) | CR20190145A (el) |
| CU (1) | CU24553B1 (el) |
| CY (1) | CY1124301T1 (el) |
| DK (1) | DK3515894T3 (el) |
| DO (1) | DOP2019000071A (el) |
| EA (1) | EA038510B1 (el) |
| EC (1) | ECSP19019589A (el) |
| ES (1) | ES2878585T3 (el) |
| HR (1) | HRP20211006T1 (el) |
| HU (1) | HUE054910T2 (el) |
| IL (1) | IL265066B (el) |
| JO (1) | JOP20190054B1 (el) |
| LT (1) | LT3515894T (el) |
| MX (1) | MX2019003362A (el) |
| MY (1) | MY196425A (el) |
| PE (1) | PE20190657A1 (el) |
| PH (1) | PH12019500327A1 (el) |
| PL (1) | PL3515894T3 (el) |
| PT (1) | PT3515894T (el) |
| RS (1) | RS62145B1 (el) |
| RU (1) | RU2749547C2 (el) |
| SG (1) | SG11201901146SA (el) |
| SI (1) | SI3515894T1 (el) |
| TW (1) | TWI651308B (el) |
| UY (1) | UY37412A (el) |
| WO (1) | WO2018055550A1 (el) |
| ZA (1) | ZA201900860B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| MX2021008303A (es) | 2019-01-11 | 2021-10-13 | Novartis Ag | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa. |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2426031C (en) * | 2000-11-02 | 2011-10-04 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| EP1347972A1 (en) | 2000-12-19 | 2003-10-01 | Smithkline Beecham Plc | Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| AU2008262038A1 (en) | 2007-06-08 | 2008-12-18 | AbbVie Deutschland GmbH & Co. KG | 5-heteroaryl substituted indazoles as kinase inhibitors |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 脂肪酸シンターゼ阻害剤 |
| ES2580961T3 (es) * | 2011-02-24 | 2016-08-30 | Nerviano Medical Sciences S.R.L. | Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa |
| WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
-
2017
- 2017-09-21 SG SG11201901146SA patent/SG11201901146SA/en unknown
- 2017-09-21 CA CA3033249A patent/CA3033249A1/en active Pending
- 2017-09-21 CU CU2019000028A patent/CU24553B1/es unknown
- 2017-09-21 TW TW106132361A patent/TWI651308B/zh active
- 2017-09-21 CR CR20190145A patent/CR20190145A/es unknown
- 2017-09-21 CN CN201780057662.4A patent/CN109715608B/zh active Active
- 2017-09-21 PL PL17784404T patent/PL3515894T3/pl unknown
- 2017-09-21 MX MX2019003362A patent/MX2019003362A/es unknown
- 2017-09-21 AR ARP170102603A patent/AR109688A1/es unknown
- 2017-09-21 PT PT177844040T patent/PT3515894T/pt unknown
- 2017-09-21 JP JP2019515633A patent/JP7007374B2/ja active Active
- 2017-09-21 KR KR1020197010512A patent/KR102490953B1/ko active IP Right Grant
- 2017-09-21 PE PE2019000680A patent/PE20190657A1/es unknown
- 2017-09-21 HU HUE17784404A patent/HUE054910T2/hu unknown
- 2017-09-21 JO JOP/2019/0054A patent/JOP20190054B1/ar active
- 2017-09-21 DK DK17784404.0T patent/DK3515894T3/da active
- 2017-09-21 EA EA201990766A patent/EA038510B1/ru not_active IP Right Cessation
- 2017-09-21 RU RU2019111883A patent/RU2749547C2/ru active
- 2017-09-21 WO PCT/IB2017/055735 patent/WO2018055550A1/en unknown
- 2017-09-21 AU AU2017332867A patent/AU2017332867B2/en active Active
- 2017-09-21 RS RS20210833A patent/RS62145B1/sr unknown
- 2017-09-21 US US15/711,984 patent/US10112907B2/en active Active
- 2017-09-21 BR BR112019005578A patent/BR112019005578A2/pt active Search and Examination
- 2017-09-21 UY UY0001037412A patent/UY37412A/es unknown
- 2017-09-21 EP EP17784404.0A patent/EP3515894B1/en active Active
- 2017-09-21 LT LTEP17784404.0T patent/LT3515894T/lt unknown
- 2017-09-21 ES ES17784404T patent/ES2878585T3/es active Active
- 2017-09-21 MY MYPI2019000713A patent/MY196425A/en unknown
- 2017-09-21 SI SI201730834T patent/SI3515894T1/sl unknown
-
2019
- 2019-02-11 ZA ZA2019/00860A patent/ZA201900860B/en unknown
- 2019-02-15 PH PH12019500327A patent/PH12019500327A1/en unknown
- 2019-02-26 IL IL265066A patent/IL265066B/en active IP Right Grant
- 2019-03-20 CL CL2019000727A patent/CL2019000727A1/es unknown
- 2019-03-20 DO DO2019000071A patent/DOP2019000071A/es unknown
- 2019-03-20 EC ECSENADI201919589A patent/ECSP19019589A/es unknown
- 2019-03-21 CO CONC2019/0002616A patent/CO2019002616A2/es unknown
-
2021
- 2021-06-24 HR HRP20211006TT patent/HRP20211006T1/hr unknown
- 2021-07-05 CY CY20211100601T patent/CY1124301T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| CY1118585T1 (el) | Ενωση βενζοθειαζολονης | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| EA202091293A1 (ru) | Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| EA201991008A1 (ru) | Новые производные нафтиридинона и их применение в лечении аритмии |